" class="no-js "lang="en-US"> Tallac Therapeutics Appoints Kevin Heller as Chief Medical Officer
Thursday, January 26, 2023

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

Tallac Therapeutics, a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Kevin N. Heller, M.D., as Chief Medical Officer.

“We are especially pleased to welcome Kevin to Tallac’s leadership team at a time when the Company is advancing novel immunotherapeutic agents in early clinical development,” said Hong I. Wan, Ph.D., president, CEO and co-founder of Tallac Therapeutics. “Kevin brings a wealth of expertise as a seasoned drug developer with a proven track record of clinical trial planning and execution. His leadership will be instrumental to the advancement of our first-in-class therapies to address the needs of patients with difficult-to-treat cancer.”

“I am thrilled to join the Tallac team at such an exciting time and look forward to supporting the progress of the Company’s clinical programs and impressive assets in the pipeline,” said Dr. Heller. “The Tallac team has demonstrated pre-clinical proof-of-concept for their novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform approach to engage both the innate and adaptive immunity to treat cancer. I look forward to working with my colleagues to translate this work and deliver new medicines to patients – starting with TAC-001, a first-in-class systemic TLR9 agonist and the first TRAAC candidate to enter the clinic.”

An experienced biopharmaceutical executive and physician, Dr. Heller brings a deep understanding of the successful development of novel oncology medicines. Previously he served as executive vice president, research and development at Jasper Therapeutics. Prior to that, he was chief medical officer at NextCure, Inc., a biotechnology company developing immunotherapy-based biologics for cancer and other diseases. Before that, he was vice president and head of antibody clinical development at Incyte, coordinating immunotherapy clinical development strategies for multiple antibody programs. He joined Incyte from AstraZeneca, where he was senior medical director, overseeing global medicines development in oncology. Dr. Heller began his biopharma industry experience at Bristol Myers Squibb, where he led early development programs and was responsible for authoring protocols and managing first-in-human clinical trials. His also served as global lead for Oncology Search and Evaluation at BMS, where he was responsible for leading a team matrix across disciplines during due diligence activities and preparing recommendations for possible acquisitions.

Dr. Heller received a Bachelor’s degree in molecular biophysics and biochemistry from Yale University and a medical degree from George Washington University. He trained in pediatrics and pediatric hematology/oncology at Memorial Sloan Kettering Cancer Center. Following his fellowship, Dr. Heller joined the faculty of the Rockefeller University as instructor and subsequently chief clinical scholar of Clinical Investigation.

  1. Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Read more
  2. Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Read more
  3. Sharecare Launches VR Program to Improve Well-being of American Workforce Read more
  4. Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Read more
  5. Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Read more